{"entity":{"id":"nct04930653","kind":"trial","name":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Methoxsalen and Mogamulizumab in Cutaneous T-cell lymphoma, Peripheral T-cell lymphomas and Non-Hodgkin lymphoma, run by City of Hope Medical Center, now recruiting.","summary":"Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma is a phase 2 interventional study registered as NCT04930653 by City of Hope Medical Center, with 34 participants planned, started 2022-10-19 and due to reach its primary completion in 2028-06-15. Interventions recorded: Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment, Questionnaire Administration. Conditions recorded: Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Transformed Mycosis Fungoides.\n\nLinked to the drug Methoxsalen because the registry names it among its interventions and Cutaneous T-cell lymphoma, Peripheral T-cell lymphomas and Non-Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.","status":"recruiting","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04930653","url":"https://clinicaltrials.gov/study/NCT04930653"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma","non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["methoxsalen-ecp","mogamulizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04930653","phase":"2","setting":"A Phase II Study of Combination Extracorporeal Photopheresis (ECP) and Mogamulizumab in Erythrodermic CTCL","sponsor":"City of Hope Medical Center","enrolled":34,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04930653/","neighbours":{"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"drug":[{"id":"methoxsalen-ecp","kind":"drug","name":"Methoxsalen (extracorporeal photopheresis)","route":"/drugs/methoxsalen-ecp/"},{"id":"mogamulizumab","kind":"drug","name":"Mogamulizumab","route":"/drugs/mogamulizumab/"}]}}